{
    "clinical_study": {
        "@rank": "92359", 
        "arm_group": [
            {
                "arm_group_label": "Group 1", 
                "arm_group_type": "Experimental", 
                "description": "Stage 4 renal impairment (estimated glomerular filtration rate (eGFR)] 15 to 29 mL/min/1.73 m2)"
            }, 
            {
                "arm_group_label": "Group 2", 
                "arm_group_type": "Experimental", 
                "description": "End stage renal disease requiring hemodialysis"
            }, 
            {
                "arm_group_label": "Group 3", 
                "arm_group_type": "Experimental", 
                "description": "Healthy subjects (estimated glomerular filtration rate (eGFR) \u2265 80 mL/min/1.73 m2)"
            }
        ], 
        "brief_summary": {
            "textblock": "This is an open-label, single-dose, parallel-group study conducted in healthy subjects and\n      subjects with stage 4 renal impairment (RI) or end stage renal disease (ESRD) requiring\n      hemodialysis to evaluate the safety, tolerability, and immunogenicity profile of\n      romosozumab. Subjects will enroll in parallel into 1 of three treatment groups to receive a\n      single dose of romosozumab."
        }, 
        "brief_title": "Study of Romosozumab (AMG 785) Administered to Healthy Subjects and Subjects With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": "Osteoporosis", 
        "condition_browse": {
            "mesh_term": [
                "Osteoporosis", 
                "Renal Insufficiency"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "INCLUSION CRITERIA - ALL SUBJECTS :\n\n          -  Males or females \u2265 50 years of age\n\n          -  Body weight \u2265 45 and \u2264 110 kg\n\n          -  Willing to adhere to calcium and vitamin D supplementation requirements\n\n          -  Females must be of non-reproductive potential\n\n        INCLUSION CRITERIA - SUBJECTS WITH RENAL IMPAIRMENT (GROUPS 1 AND 2):\n\n          -  Group 1 - Stage 4 RI (estimated glomerular filtration rate (eGFR) 15-29 mL/min/1.73\n             m2)\n\n          -  Group 2 - End stage renal disease requiring hemodialysis\n\n        INCLUSION CRITERIA - HEALTHY SUBJECTS (GROUP 3):\n\n        \u2022 Renal function defined as an - estimated glomerular filtration rate (eGFR) \u2265 80\n        mL/min/1.73 m2\n\n        EXCLUSION CRITERIA - ALL SUBJECTS:\n\n          -  History of metabolic or bone disease (except for metabolic bone disease in renal\n             impairment (RI) subjects)\n\n          -  History of osteoporosis, vertebral fracture, or fragility fracture of the wrist,\n             humerus, hip, or pelvis after age 50\n\n          -  Recent bone fracture\n\n          -  Vitamin D insufficiency\n\n          -  Hypocalcemia or hypercalcemia\n\n          -  Hypomagnesemia\n\n          -  Hypophosphatemia\n\n          -  Untreated hyper- or hypothyroidism\n\n          -  Females with a positive pregnancy test\n\n          -  Males with pregnant partners\n\n          -  Females who are lactating/breastfeeding or plan to breastfeed on study and for 3\n             months after receiving the dose of study drug\n\n          -  History of spinal stenosis\n\n          -  History of facial nerve paralysis\n\n          -  Positive for human immunodeficiency virus (HIV) antibodies\n\n          -  Positive for hepatitis B surface antigen or detectable hepatitis C\n\n          -  Malignancy (except fully resected cutaneous basal cell or squamous cell carcinoma,\n             cervical, or breast ductal carcinoma in situ) within 5 years before screening\n\n          -  History of solid organ or bone marrow transplants EXCLUSION CRITERIA - HEALTHY\n             SUBJECTS (GROUP 3)\n\n          -  Current hyper- or hypoparathyroidism"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01833754", 
            "org_study_id": "20110227"
        }, 
        "intervention": {
            "arm_group_label": [
                "Group 1", 
                "Group 2", 
                "Group 3"
            ], 
            "description": "Subcutaneous, Single Dose, Single Dose Level", 
            "intervention_name": "Romosozumab", 
            "intervention_type": "Drug", 
            "other_name": "AMG 785"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Osteoporosis, Bone, Renal, Insufficiency, Kidney, Hemodialysis, Impairment", 
        "lastchanged_date": "April 14, 2014", 
        "link": {
            "description": "AmgenTrials clinical trials website", 
            "url": "http://www.amgentrials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Tempe", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85284"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90022"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80230"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pembroke Pines", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33028"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orangeburg", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29118"
                    }, 
                    "name": "Research Site"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 1, Open-label, Single-dose Study of Romosozumab (AMG 785) Administered Subcutaneously to Healthy Subjects and Subjects With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis", 
        "overall_official": {
            "affiliation": "Amgen", 
            "last_name": "MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "\u2022 Subject incidence of treatment-emergent adverse events \u2022 Results of safety laboratory tests, vital sign measurements, and ECG measurements \u2022 Subject incidence of anti-romosozumab antibodies", 
            "safety_issue": "Yes", 
            "time_frame": "85 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01833754"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Romosozumab serum PK parameters (ie, area under the curve [AUClast, AUCinf], maximum observed concentration [Cmax], and time to reach maximum observed concentration [tmax]): Concentration-time profiles for romosozumab", 
            "measure": "Romosozumab PK parameters", 
            "safety_issue": "No", 
            "time_frame": "15 timepoints, 85 days"
        }, 
        "source": "Amgen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Amgen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}